| Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo … HM Colhoun, DJ Betteridge, PN Durrington, GA Hitman, HAW Neil, ... The Lancet 364 (9435), 685-696, 2004 | 5567 | 2004 |
| 2016 ESC/EAS guidelines for the management of dyslipidaemias AL Catapano, I Graham, G De Backer, O Wiklund, MJ Chapman, H Drexel, ... Polish Heart Journal (Kardiologia Polska) 74 (11), 1234-1318, 2016 | 4819 | 2016 |
| European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other … I Graham, D Atar, K Borch-Johnsen, G Boysen, G Burell, R Cifkova, ... European heart journal 28 (19), 2375-2414, 2007 | 4135 | 2007 |
| ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European … Ž Reiner, AL Catapano, G De Backer, I Graham, MR Taskinen, O Wiklund, ... European heart journal 32 (14), 1769-1818, 2011 | 3892 | 2011 |
| Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein MI Mackness, S Arrol, PN Durrington FEBS letters 286 (1-2), 152-154, 1991 | 1373 | 1991 |
| Paraoxonase and atherosclerosis PN Durrington, B Mackness, MI Mackness Arteriosclerosis, thrombosis, and vascular biology 21 (4), 473-480, 2001 | 1244 | 2001 |
| ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European … AL Catapano, Ž Reiner, G De Backer, I Graham, MR Taskinen, O Wiklund, ... Atherosclerosis 217, 1-44, 2011 | 1176 | 2011 |
| Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase MI Mackness, S Arrol, C Abbott, PN Durrington Atherosclerosis 104 (1-2), 129-135, 1993 | 1119 | 1993 |
| Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis SM Boekholdt, BJ Arsenault, S Mora, TR Pedersen, JC LaRosa, PJ Nestel, ... Jama 307 (12), 1302-1309, 2012 | 1039 | 2012 |
| Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review L Hooper, RL Thompson, RA Harrison, CD Summerbell, AR Ness, ... Bmj 332 (7544), 752-760, 2006 | 1020 | 2006 |
| LMNA, encoding lamin A/C, is mutated in partial lipodystrophy S Shackleton, DJ Lloyd, SNJ Jackson, R Evans, MF Niermeijer, BM Singh, ... Nature genetics 24 (2), 153-156, 2000 | 836 | 2000 |
| Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials J Armitage, C Baigent, E Barnes, DJ Betteridge, L Blackwell, M Blazing, ... The Lancet 393 (10170), 407-415, 2019 | 748 | 2019 |
| Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins MI Mackness, B Mackness, PN Durrington, PW Connelly, RA Hegele Current opinion in lipidology 7 (2), 69-76, 1996 | 719 | 1996 |
| Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus MI Mackness, D Harty, D Bhatnagar, PH Winocour, S Arrol, M Ishola, ... Atherosclerosis 86 (2-3), 193-199, 1991 | 685 | 1991 |
| Dyslipidaemia P Durrington The Lancet 362 (9385), 717-731, 2003 | 667 | 2003 |
| Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel PJ Barter, CM Ballantyne, R Carmena, MC Cabezas, MJ Chapman, ... Journal of internal medicine 259 (3), 247-258, 2006 | 656 | 2006 |
| Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? B Mackness, GK Davies, W Turkie, E Lee, DH Roberts, E Hill, C Roberts, ... Arteriosclerosis, thrombosis, and vascular biology 21 (9), 1451-1457, 2001 | 654 | 2001 |
| HDL, its enzymes and its potential to influence lipid peroxidation MI Mackness, PN Durrington Atherosclerosis 115 (2), 243-253, 1995 | 606 | 1995 |
| Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study B Mackness, P Durrington, P McElduff, J Yarnell, N Azam, M Watt, ... Circulation 107 (22), 2775-2779, 2003 | 601 | 2003 |
| Human serum paraoxonase B Mackness, PN Durrington, MI Mackness General Pharmacology: The Vascular System 31 (3), 329-336, 1998 | 588 | 1998 |
